The interplay between epigenetic silencing, oncogenic KRas and HIF-1 regulatory pathways in control of BNIP3 expression in human colorectal cancer cells

Biochemical and Biophysical Research Communications

Volumn 441, Issue 4, 2013, Pages 707-712

  Swiderek, Ewelina ^a   Kalas, Wojciech ^a   Wysokinska, Edyta ^a   Pawlak, Alicja ^a   Rak, Janusz ^b   Strzadala, Leon ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

5 Aza 2' deoxycytidine; BNIP3; Colorectal cancer; HIF 1; Hypoxia; KRas

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; K RAS PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BNIP3; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR E2F1; TRANSFER RNA;

ARTICLE; CELL SURVIVAL; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; DEMETHYLATION; DOWN REGULATION; ENZYME ACTIVITY; EPIGENETICS; GENE SILENCING; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; UPREGULATION; WESTERN BLOTTING;

ADENOVIRIDAE;

5-AZA-2′-DEOXYCYTIDINE; BNIP3; COLORECTAL CANCER; HIF-1; HYPOXIA; KRAS;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL HYPOXIA; COLORECTAL NEOPLASMS; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HT29 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MEMBRANE PROTEINS; METABOLIC NETWORKS AND PATHWAYS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84888835068     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.10.098     Document Type: Article

References (33)

1. White E. Role of the metabolic stress responses of apoptosis and autophagy in tumor suppression. Ernst Schering Found. Symp. Proc. 2007, 23-34.
2. Swiderek E., Strzadała L. Autophagy and BNIP3 protein in tumorogenesis. Postepy Hig. Med. Dosw. (Online) 2013, 67:363-370.
3. Mellor H.R., Harris A.L. The role of the hypoxia-inducible BH3-only proteins BNIP3 and BNIP3L in cancer. Cancer Metastasis Rev. 2007, 26:553-566.
4. Lee H., Paik S.-G. Regulation of BNIP3 in normal and cancer cells. Mol. Cells 2006, 21:1-6.
5. Murai M., Toyota M., Suzuki H., et al. Aberrant methylation and silencing of the BNIP3 gene in colorectal and gastric cancer. Clin. Cancer Res. 2005, 11:1021-1027.
6. Okami J., Simeone D.M., Logsdon C.D. Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer. Cancer Res. 2004, 64:5338-5346.
7. Hiraki M., Kitajima Y., Nakafusa Y., et al. CpG island methylation of BNIP3 predicts resistance against S-1/CPT-11 combined therapy in colorectal cancer patients. Oncol. Rep. 2010, 23:191-197.
8. Ishiguro M., Iida S., Uetake H., et al. Effect of combined therapy with low-dose 5-aza-2'-deoxycytidine and irinotecan on colon cancer cell line HCT-15. Ann. Surg. Oncol. 2007, 14:1752-1762.
9. Cosse J.P., Rommelaere G., Ninane N., et al. BNIP3 protects HepG2 cells against etoposide-induced cell death under hypoxia by an autophagy-independent pathway. Biochem. Pharmacol. 2010, 80(8):1160-1169.
10. Burton T.R., Eisenstat D.D., Gibson S.B. BNIP3 (Bcl-2 19kDa interacting protein) acts as transcriptional repressor of apoptosis-inducing factor expression preventing cell death in human malignant gliomas. J. Neurosci. 2009, 29:4189-4199.
11. Burton T.R., Henson E.S., Azad M.B., et al. BNIP3 acts as transcriptional repressor of death receptor-5 expression and prevents TRAIL-induced cell death in gliomas. Cell Death Dis. 2013, 4:e587.
12. Swoboda E., Strzadała L. BNIP3 as an atypical representative of the Bcl-2 protein family. Part 2: regulation of the expression and activity of BNIP3 protein and its role in tumorigenesis. Postepy Hig. Med. Dosw. (Online) 2009, 63:418-424.
13. Shaw J., Yurkova N., Zhang T., et al. Antagonism of E2F-1 regulated Bnip3 transcription by NF-kappaB is essential for basal cell survival. Proc. Natl. Acad. Sci. USA 2008, 105:20734-20739.
14. Yurkova N., Shaw J., Blackie K., et al. The cell cycle factor E2F-1 activates Bnip3 and the intrinsic death pathway in ventricular myocytes. Circ. Res. 2008, 102:472-479.
15. Yang S., Wang X., Contino G., et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev. 2011, 25:717-729.
16. Yoo B.H., Wu X., Li Y., et al. Oncogenic ras-induced down-regulation of autophagy mediator Beclin-1 is required for malignant transformation of intestinal epithelial cells. J. Biol. Chem. 2010, 285:5438-5449.
17. Kalas W., Swiderek E., Switalska M., et al. Thrombospondin-1 receptor mediates autophagy of RAS-expressing cancer cells and triggers tumour growth inhibition. Anticancer Res. 2013, 33:1429-1438.
18. Crea F., Giovannetti E., Cortesi F., et al. Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines. Mol. Cancer Ther. 2009, 8:1964-1973.
19. Liu F., Liu Q., Yang D., et al. Verticillin A overcomes apoptosis resistance in human colon carcinoma through DNA methylation-dependent upregulation of BNIP3. Cancer Res. 2011, 71:6807-6816.
20. Valdez B.C., Li Y., Murray D., et al. 5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis. Leuk. Res. 2010, 34:364-372.
21. Ray R., Chen G., Vande C. Velde, et al., BNIP3 heterodimerizes with Bcl-2/Bcl-X(L) and induces cell death independent of a Bcl-2 homology 3 (BH3) domain at both mitochondrial and nonmitochondrial sites. J. Biol. Chem. 2000, 275:1439-1448.
22. Emerling B.M., Weinberg F., Liu J.-L., et al. PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a). Proc. Natl. Acad. Sci. USA 2008, 105:2622-2627.
23. Shirasawa S., Furuse M., Yokoyama N., et al. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993, 260:85.
24. MacLeod A.R., Rouleau J., Szyf M. Regulation of DNA methylation by the Ras signaling pathway. J. Biol. Chem. 1995, 270:11327-11337.
25. Yoon J., Koo K.-H., Choi K.-Y. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. Cancer Res. 2011, 71:445-453.
26. An H.-J., Lee H., Paik S.-G. Silencing of BNIP3 results from promoter methylation by DNA methyltransferase 1 induced by the mitogen-activated protein kinase pathway. Mol. Cells 2011, 31:579-583.
27. Kalas W., Swiderek E., Rapak A., et al. H-ras up-regulates expression of BNIP3. Anticancer Res. 2011, 31:2869-2875.
28. An H.-J., Maeng O., Kang K.-H., et al. Activation of Ras up-regulates pro-apoptotic BNIP3 in nitric oxide-induced cell death. J. Biol. Chem. 2006, 281:33939-33948.
29. Berkovich E., Ginsberg D. Ras induces elevation of E2F-1 mRNA levels. J. Biol. Chem. 2001, 276:42851-42856.
30. Tracy K., Macleod K.F. Regulation of mitochondrial integrity, autophagy and cell survival by BNIP3. Autophagy 2007, 3:616-619.
31. Shimizu S., Iida S., Ishiguro M., et al. Methylated BNIP3 gene in colorectal cancer prognosis. Oncol. Lett. 2010, 1:865-872.
32. Erkan M., Kleeff J., Esposito I., et al. Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene 2005, 24:4421-4432.
33. Vijayalingam S., Pillai S.G., Rashmi R., et al. Overexpression of BH3-only protein BNIP3 leads to enhanced tumor growth. Genes Cancer 2010, 1:964-971.